Stock Taper 
Amphastar Pharmaceuticals develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products for healthcare providers in the US, China, and France, serving hospitals, clinics, and care facilities.
Baqsimi, the first nasal glucagon for severe hypoglycemia, was acquired from Eli Lilly in 2023 for over $1 billion, strengthening Amphastar's diabetes care portfolio with a needle-free emergency treatment.
Amphastar Pharmaceuticals received FDA approval on December 15, 2025, for its teriparatide injection, a generic equivalent to Eli Lilly's FORTEO used for treating osteoporosis. This approval is particularly noteworthy as it is Amphastar's first pen device combination product, showcasing the company's capability in developing complex drug delivery systems and opening up a significant market opportunity.
In 2025, Amphastar Pharmaceuticals' leadership made a significant strategic shift to fundamentally transform its business model, moving away from its historical reliance on generic drugs to focus on higher-margin proprietary and biosimilar products. This strategic evolution is intended to dramatically reshape the company's pipeline, aiming to reduce its generic portfolio to just 15% by 2026, down from 63% in 2021, while increasing proprietary products to 50% and biosimilars to 35%.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) has been given a consensus recommendation of "Reduce" by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average twelve-month price target among
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
 RDY | $12.31 | COMPARE |
 ALKS | $42.77 | COMPARE |
 SNDX | $20.13 | COMPARE |
 ANIP | $72.18 | COMPARE |
 HROW | $40.40 | COMPARE |
 INBX | $80.90 | COMPARE |
 PCRX | $24.84 | COMPARE |
 AHCO | $5.92 | COMPARE |
